Published in Antimicrob Agents Chemother on March 01, 1983
In vitro studies of investigational beta-lactams as possible therapy for Pseudomonas aeruginosa endocarditis. Antimicrob Agents Chemother (1985) 0.82
Single-dose pharmacokinetics of cefsulodin in patients with cystic fibrosis. Antimicrob Agents Chemother (1984) 0.79
The biotransformation of drugs in renal failure. Am J Med (1977) 1.70
[Total joint surfact replacement in the hip joint. Preliminary communication]. Arch Orthop Unfallchir (1975) 1.47
Cefsulodin kinetics in renal impairment. Clin Pharmacol Ther (1982) 1.37
Cefsulodin kinetics in healthy subjects after intramuscular and intravenous injection. Clin Pharmacol Ther (1982) 1.14
Prediction of drug dosage in patients with renal failure using data derived from normal subjects. Clin Pharmacol Ther (1975) 1.00
Precise high-performance liquid chromatographic procedure for the determination of cefsulodin, a new antipseudomonal cephalosporin antibiotic, in plasma. J Pharm Sci (1982) 0.95
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med (2001) 22.32
Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet (1995) 4.06
Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med (1989) 2.94
Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis (1999) 2.38
Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother (1984) 2.09
Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet (1986) 2.07
The glomerular mesangium. Kidney Int (1980) 1.83
Experimental pyelonephritis. XIV. Pyelonephritis in normal mice produced by inoculation of E. coli into the bladder lumen during water diuresis. Yale J Biol Med (1967) 1.67
Mechanism of Escherichia coli alpha-hemolysin-induced injury to isolated renal tubular cells. Am J Pathol (1987) 1.57
Intravenous iron supplementation in end-stage renal disease patients. Am J Kidney Dis (1999) 1.57
Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med (1993) 1.54
Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Ann Intern Med (1994) 1.44
Antimicrobial treatment of peritonitis associated with continuous ambulatory peritoneal dialysis. Perit Dial Int (1991) 1.42
A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine (2001) 1.41
Bacterial growth and killing in chronic ambulatory peritoneal dialysis fluids. J Clin Microbiol (1984) 1.36
The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst (2000) 1.35
Peritoneal macrophages and opsonins: antibacterial defense in patients undergoing chronic peritoneal dialysis. J Infect Dis (1983) 1.35
Cefotaxime and desacetyl cefotaxime kinetics in renal impairment. Clin Pharmacol Ther (1985) 1.34
Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? Lancet (1996) 1.34
Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. Clin Pharmacol Ther (1997) 1.33
Pharmacokinetics of cefepime in subjects with renal insufficiency. Clin Pharmacol Ther (1990) 1.32
Pharmacokinetics of ciprofloxacin in acutely ill and convalescent elderly patients. Am J Med (1987) 1.30
Opsonic deficiency of peritoneal dialysis effluent in continuous ambulatory peritoneal dialysis. Kidney Int (1984) 1.29
Effects of magnesium-aluminum hydroxide and calcium carbonate antacids on bioavailability of ofloxacin. Antimicrob Agents Chemother (1990) 1.28
Proteinuria is a risk factor for mortality over 10 years of follow-up. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Kidney Int Suppl (1997) 1.28
Systemic absorption of oral vancomycin in patients with renal insufficiency and antibiotic-associated colitis. Am J Kidney Dis (1987) 1.23
Renal injury of diet-induced hypercholesterolemia in rats. Kidney Int (1990) 1.21
Ethylene glycol poisoning: pharmacokinetics during therapy with ethanol and hemodialysis. N Engl J Med (1981) 1.21
The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension (1992) 1.20
Current concepts in the management of peritonitis in patients undergoing continuous ambulatory peritoneal dialysis. Rev Infect Dis (1987) 1.19
Safety and pharmacokinetics of multiple doses of intravenous ofloxacin in healthy volunteers. Antimicrob Agents Chemother (1992) 1.16
Survival and rehabilitation of patients on home hemodialysis. Five years' experience. Ann Intern Med (1973) 1.13
Disposition of the cephalosporin cefepime in normal and renally impaired subjects. Drug Metab Dispos (1991) 1.13
Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res (1988) 1.13
A primer on continuous renal replacement therapy for critically ill patients. Ann Pharmacother (1998) 1.10
Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int (1988) 1.09
Opioid-mediated suppression of interferon-gamma production by cultured peripheral blood mononuclear cells. J Clin Invest (1987) 1.09
Intracellular survival of Candida albicans in peritoneal macrophages from chronic peritoneal dialysis patients. Am J Kidney Dis (1986) 1.08
Validity of creatinine clearance estimates in the assessment of renal function. Clin Pharmacol Ther (1990) 1.07
Enhancement of endotoxin-induced isolated renal tubular cell injury by toxic shock syndrome toxin 1. Am J Pathol (1986) 1.04
Unintended immunomodulation: part II. Effects of pharmacological agents on cytokine activity. Shock (2000) 1.04
Incidence and type of infections occurring in 445 chronic hemodialysis patients. Trans Am Soc Artif Intern Organs (1977) 1.03
Cefazolin as empiric therapy in hemodialysis-related infections: efficacy and blood concentrations. Am J Kidney Dis (1998) 1.02
Recent advances in statins and the kidney. Kidney Int Suppl (1999) 1.01
Disposition of gabapentin in anuric subjects on hemodialysis. J Clin Pharmacol (1995) 0.99
Pharmacokinetics of vancomycin in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother (1984) 0.99
Glomerular hemodynamic and structural alterations in experimental diabetes mellitus. FASEB J (1988) 0.98
Opioid peptides rapidly stimulate superoxide production by human polymorphonuclear leukocytes and macrophages. Endocrinology (1985) 0.98
Opioid-mediated suppression of cultured peripheral blood mononuclear cell respiratory burst activity. J Immunol (1987) 0.98
Unilateral Shwartzman reaction: cortical necrosis in one kidney following in vivo perfusion with endotoxin. Kidney Int (1977) 0.98
Pharmacokinetics of tazobactam M1 metabolite after administration of piperacillin/tazobactam in subjects with renal impairment. J Clin Pharmacol (1994) 0.96
Effects of genetic obesity on renal structure and function in the Zucker rat. J Lab Clin Med (1985) 0.96
Role of hypertension in progressive glomerular immune injury. Hypertension (1985) 0.96
Medication knowledge and compliance among patients receiving long-term dialysis. Am J Health Syst Pharm (1995) 0.96
Relationship among altered glomerular barrier permselectivity, angiotensin II, and mesangial uptake of macromolecules. Lab Invest (1985) 0.95
Protein binding of disopyramide and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients. Am J Nephrol (1985) 0.95
Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Am J Kidney Dis (1998) 0.93
Early glomerular changes in rats with dietary-induced hypercholesterolemia. Am J Kidney Dis (1995) 0.93
Disposition of vancomycin during hemofiltration. Clin Pharmacol Ther (1986) 0.93
Treating severe metabolic alkalosis. Clin Pharm (1983) 0.92
Lovastatin but not enalapril reduces glomerular injury in Dahl salt-sensitive rats. Hypertension (1992) 0.92
Cholesterol-lowering effects of calcium carbonate in patients with mild to moderate hypercholesterolemia. Arch Intern Med (1992) 0.92
Opsonization of Legionella pneumophila in human serum: key roles for specific antibodies and the classical complement pathway. Immunology (1985) 0.91
Codeine dosage in renal failure. Clin Pharm (1986) 0.90
Effects of genetic obesity on renal structure and function in the Zucker rat. II. Micropuncture studies. J Lab Clin Med (1985) 0.90
Small molecule selectin ligand inhibition improves outcome in ischemic acute renal failure. Kidney Int (2001) 0.90
Evaluation of the vancomycin-clearance:creatinine-clearance relationship for predicting vancomycin dosage. Clin Pharm (1985) 0.89
Lovastatin retards the progression of established glomerular disease in obese Zucker rats. Am J Kidney Dis (1993) 0.89
Polyamino acid enhancement of bacterial phagocytosis by human polymorphonuclear leukocytes and peritoneal macrophages. Infect Immun (1984) 0.89
Adriamycin-induced chronic proteinuria: a structural and functional study. J Lab Clin Med (1985) 0.88
Controlled comparison of gentamicin and tobramycin nephrotoxicity. Am J Nephrol (1983) 0.88
Central role of the transcription factor nuclear factor-kappa B in mesangial cell production of chemokines. Contrib Nephrol (1997) 0.88
Pharmacokinetics of codeine after single- and multiple-oral-dose administration to normal volunteers. J Clin Pharmacol (1987) 0.88
Pharmacokinetics of cefepime in patients with respiratory tract infections. Antimicrob Agents Chemother (1990) 0.88
Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest (1993) 0.87
Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease. Clin Pharmacol Ther (1988) 0.87
Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment. J Clin Pharmacol (1991) 0.87
Lipid abnormalities in end stage renal disease. Nephrol Dial Transplant (1998) 0.87
Renal cell cytokine production stimulates HIV-1 expression in chronically HIV-1-infected monocytes. Kidney Int (1998) 0.87
Antimicrobial activities of dialysate-elicited and resident human peritoneal macrophages. Infect Immun (1985) 0.87
Use of chlorzoxazone as an in vivo probe of cytochrome P450 2E1: choice of dose and phenotypic trait measure. J Clin Pharmacol (1998) 0.86
Mononuclear phagocytic system stimulation. Protective role from glomerular immune complex deposition. J Lab Clin Med (1981) 0.86
Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin. Biochem Biophys Res Commun (2000) 0.86
Hyperlipidemia in the nephrotic syndrome. N Engl J Med (1990) 0.86
Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats. Am J Kidney Dis (1998) 0.85
The central role of nuclear factor-kappa B in mesangial cell activation. Kidney Int Suppl (1999) 0.85
Determinants of glomerular filtration and plasma flow in experimental diabetic rats. J Lab Clin Med (1981) 0.85
Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure. Kidney Int (2001) 0.85
Teicoplanin pharmacokinetics in patients undergoing continuous ambulatory peritoneal dialysis after intravenous and intraperitoneal dosing. Antimicrob Agents Chemother (1989) 0.85
Lovastatin inhibits lipopolysaccharide-induced NF-kappaB activation in human mesangial cells. Nephrol Dial Transplant (1996) 0.85
Impaired mesangial clearance of macromolecules in rats with chronic mesangial ferritin-antiferritin immune complex deposition. Lab Invest (1980) 0.85
Perinephric abscess in patients with polycystic kidney disease undergoing chronic hemodialysis. Nephron (1979) 0.85
Effect of ceftazidime on systemic cytokine concentrations in rats. Antimicrob Agents Chemother (2000) 0.84
The national epidemic of chronic kidney disease. What we know and what we can do. Postgrad Med (2001) 0.84